These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12457438)

  • 1. Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
    Patel SR
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1789-93. PubMed ID: 12457438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic strategies for soft tissue sarcomas.
    von Mehren M
    Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Italiano A; Toulmonde M; Bui-Nguyen B
    Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
    Sharma S; Takyar S; Manson SC; Powell S; Penel N
    BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
    Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
    Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of soft tissue sarcomas.
    Cassier PA; Dufresne A; Fayette J; Alberti L; Ranchere D; Ray-Coquard I; Blay JY
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):139-53. PubMed ID: 17355219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in systemic therapy of soft tissue sarcomas.
    Patel SR
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):179-84. PubMed ID: 12722877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
    Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F
    Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic management strategies for metastatic soft tissue sarcoma.
    Movva S; Verschraegen C
    Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New agents in cancer clinical trials.
    Adams J; Elliott PJ
    Oncogene; 2000 Dec; 19(56):6687-92. PubMed ID: 11426656
    [No Abstract]   [Full Text] [Related]  

  • 13. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
    Bertino P; Piccardi F; Porta C; Favoni R; Cilli M; Mutti L; Gaudino G
    Clin Cancer Res; 2008 Jan; 14(2):541-8. PubMed ID: 18223230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of systemic therapy in sarcoma.
    Constantinidou A; Pollack S; Loggers E; Rodler E; Jones RL
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):211-23. PubMed ID: 23406562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
    Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
    Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
    Heinrich MC; Corless CL
    Cancer Treat Res; 2004; 120():129-50. PubMed ID: 15217222
    [No Abstract]   [Full Text] [Related]  

  • 19. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    Stroobants S; Goeminne J; Seegers M; Dimitrijevic S; Dupont P; Nuyts J; Martens M; van den Borne B; Cole P; Sciot R; Dumez H; Silberman S; Mortelmans L; van Oosterom A
    Eur J Cancer; 2003 Sep; 39(14):2012-20. PubMed ID: 12957455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.